Abcam, ab265107, Human ESRP2 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
ESRP2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ESRP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ESRP2 also known as Epithelial Splicing Regulatory Protein 2 plays a role in how RNA undergoes alternative splicing. This protein is part of the larger family of RNA-binding proteins that modulate the splicing of pre-mRNA in an epithelial cell context. ESRP2 has a molecular weight of approximately 76 kDa. It is expressed mainly in epithelial tissues including the lung kidney and intestine. Human ESRP2 encodes a protein that controls variations in mRNA which leads to different protein isoforms.
Biological function summary
ESRP2 regulates epithelial cell phenotypes by influencing the expression of genes specific to epithelial tissues. It forms a complex with ESRP1 another RNA-binding protein enhancing its ability to control RNA splicing events. The ESRP2 protein affects the alternative splicing of pre-mRNAs encoding proteins that contribute to cell adhesion motility and signaling pathways. This precise regulation of mRNA variants is critical for maintaining epithelial cellular identity and function.
Pathways
The involvement of ESRP2 in RNA splicing impacts the epithelial-mesenchymal transition (EMT) pathway. This is key in developmental processes and cancer metastasis where ESRP2 partners with ESRP1 to regulate the splice variants of genes important for EMT like FGFR2. ESRP2 affects the inclusion or exclusion of certain exons driving variation in receptor forms that have different biological outcomes influencing cell signaling and adhesion properties.
ESRP2 has significant associations with cancer progression particularly in epithelial tumors such as breast cancer and prostate cancer. Abnormal ESRP2 expression can lead to changes in EMT-related gene splicing fostering metastasis and advanced tumor states. In the context of prostate cancer ESRP2 interacts with FGFR2 and influences cancer cell invasiveness by altering specific splicing patterns highlighting its potential as a therapeutic target in cancer treatment.